Jade Biosciences, Inc. (JBIO) vs SpyGlass Pharma, Inc. Common Stock (SGP)
A side-by-side comparison of Jade Biosciences, Inc. and SpyGlass Pharma, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
JBIO
Jade Biosciences, Inc.
$13.41HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SGP
SpyGlass Pharma, Inc. Common Stock
$24.78HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — JBIO vs SGP
growth of $100 · dividends reinvested · last 1yJBIO -8.2% (-8.2%/yr)SGP -3.1% (-3.1%/yr)SGP compounded faster over this window
JBIO SGP
JBIO vs SGP: by the numbers
- •SGP is the larger company ($828M vs $816M market cap).
Metrics side by side
Valuation
| Metric | JBIO | SGP |
|---|---|---|
| P/B ratio | 1.86 | 3.57 |
Profitability
| Metric | JBIO | SGP |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -34.83% | -24.12% |
| ROIC | -37.39% | -26.54% |
Growth (annualized)
| Metric | JBIO | SGP |
|---|---|---|
| Total return CAGR (5Y) | -52.65% | N/A |
Go deeper
Dig into the metrics
Jade Biosciences ROESpyGlass Pharma, Inc. Common Stock ROEJade Biosciences operating marginSpyGlass Pharma, Inc. Common Stock operating marginJade Biosciences revenue growthSpyGlass Pharma, Inc. Common Stock revenue growthJade Biosciences free cash flowSpyGlass Pharma, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.